Puma Biotechnology

Puma Biotechnology is a biopharmaceutical company that focuses on the development and commercialization of innovative products to enhance cancer care. The company was founded in 2010 by Alan H. Auerbach, who also serves as the CEO and President. Puma Biotechnology is headquartered in Los Angeles, California, and is publicly traded on the NASDAQ under the ticker symbol "PBYI".

History

Puma Biotechnology was established in September 2010 by Alan H. Auerbach, who previously founded and led Cougar Biotechnology. Cougar Biotechnology was acquired by Johnson & Johnson in 2009. Puma Biotechnology's initial public offering (IPO) took place in April 2012.

Products

Puma Biotechnology's lead product is Neratinib, a tyrosine kinase inhibitor that has been approved by the Food and Drug Administration (FDA) for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer. Neratinib is marketed under the brand name Nerlynx.

Research and Development

Puma Biotechnology is actively involved in the research and development of new drugs and therapies. The company's R&D efforts are primarily focused on the field of oncology, with a particular emphasis on breast cancer and other HER2-positive cancers.

Financials

As a publicly traded company, Puma Biotechnology's financial information is available to the public. The company's revenue primarily comes from the sales of its lead product, Neratinib.

See Also

• Biopharmaceutical
• Oncology
• HER2/neu
• Breast Cancer

References

<references />

External Links

• Official Website

This article is a stub related to pharmacology. You can help WikiMD by expanding it!